Arrowhead Pharmaceuticals Inc
Statements
Cash Flow
Arrowhead Pharmaceuticals Inc (ARWR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -177 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10 | 10 | -14 | -10 | -9.2 | -15 | -15 | -14 | -2.7 | 168 | -20 | 11 | 14 | -24 | -28 | -33 | -11 | -39 | 264 | -30 | -24 | -61 | 63 | -69 | -69 | -76 | -32 | -21 | -25 | -118 | -92 | -115 | -137 | -146 | 460 | -155 | 20 | 13 | 84 | -177 | -59 | |
| 0.8 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.0 | 1.1 | 1.3 | 1.4 | 1.5 | 1.8 | 1.8 | 1.9 | 2.0 | 2.5 | 2.6 | 2.6 | 2.6 | 2.7 | 2.7 | 2.7 | 3.3 | 3.9 | 4.3 | 4.5 | 4.8 | 5.0 | 5.2 | 6.1 | 6.2 | 6.4 | 6.4 | 6.4 | 6.7 | 26 | |
| 4.0 | 2.4 | 1.7 | 1.7 | 2.0 | 2.1 | 1.5 | 2.3 | 2.6 | 2.7 | 2.6 | 2.0 | 5.1 | 4.5 | 13 | 10 | 16 | 8.1 | 15 | 19 | 35 | 25 | 34 | 33 | 29 | 19 | 21 | 20 | 18 | 20 | 18 | 17 | 19 | 15 | 16 | 13 | 19 | 19 | 17 | 15 | 70 | |
| 0.8 | 0.9 | 1.8 | 1.7 | 2.6 | 1.6 | 1.5 | 2.3 | 2.6 | 2.7 | 2.6 | 2.0 | 5.5 | 4.5 | 13 | 10 | 16 | 8.1 | 15 | 18 | 35 | 25 | 38 | 35 | 28 | 19 | 21 | 20 | 21 | – | – | – | – | – | – | – | – | – | – | – | – | |
| 10 | 20 | -11 | -7.6 | -2.4 | -4.4 | -3.4 | -2.5 | 4.4 | 153 | -48 | -13 | -4.5 | -27 | -22 | -32 | 20 | -28 | 274 | -20 | 2.0 | -25 | -19 | -40 | -14 | -59 | -107 | 56 | 59 | -11 | 3.4 | 25 | 8.0 | -7.4 | 46 | -18 | -38 | -62 | 199 | -46 | 53 | |
| 2.7 | 5.3 | 1.4 | 1.2 | 0.1 | 0.1 | 0.4 | 0.2 | 0.7 | 0.7 | 0.2 | 3.2 | 7.8 | 4.3 | 3.6 | 2.1 | 1.9 | 4.3 | 7.2 | 3.9 | 8.2 | 5.8 | 4.8 | 9.5 | 33 | 39 | 27 | 47 | 64 | 69 | 34 | 14 | 24 | 7.5 | 5.3 | 2.4 | 7.5 | 2.1 | 2.6 | 3.9 | 16 | |
| -1.7 | -5.3 | -26 | -13 | -4.2 | 1.4 | 17 | -29 | 3.2 | -68 | -11 | 14 | 17 | 9.3 | -178 | -6.0 | -66 | 30 | -34 | -20 | -118 | -33 | -70 | 61 | 36 | -81 | -36 | -9.9 | 31 | 65 | -269 | 6.9 | -223 | 77 | -420 | 141 | 73 | -24 | -894 | 44 | -802 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 42 | 38 | – | |
| 54 | -0.4 | 0.2 | 12 | 0.0 | 0.2 | -0.1 | 1.5 | 1.6 | 62 | 2.7 | 2.8 | 69 | 253 | 1.3 | 2.1 | 1.0 | 5.1 | 2.6 | 2.8 | 0.8 | 1.9 | 1.8 | 0.6 | 0.9 | 0.6 | 0.5 | 1.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.1 | 0.0 | 0.0 | -0.1 | -0.1 | -0.2 | 0.1 | -0.1 | -0.1 | -2.4 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 250 | 250 | 250 | – | – | – | – | – | 0.0 | -152 | -50 | 10 | -67 | 812 | -33 | 722 | |
| 54 | 12 | 0.1 | -0.3 | -0.1 | 0.0 | 57 | 1.5 | 1.6 | 59 | 2.7 | 2.8 | 1.8 | 253 | 1.3 | 2.1 | 1.0 | 5.1 | 2.6 | 2.8 | 0.8 | 1.9 | 1.8 | 61 | 0.9 | 251 | 0.5 | 1.1 | 0.2 | 0.3 | 431 | 50 | 389 | 21 | 92 | -43 | 3.7 | -15 | 796 | -0.4 | 784 | |
| 42 | 17 | -40 | -23 | -14 | -13 | 58 | -42 | 2.1 | 160 | -28 | 28 | 32 | 239 | -204 | -37 | -76 | -3.7 | 232 | -46 | -142 | -93 | -5.2 | 53 | -31 | 94 | -67 | -30 | 5.6 | -53 | 69 | -58 | 33 | -49 | 132 | -56 | 97 | -25 | -13 | -134 | -75 | |
| -13 | 4.7 | -16 | -12 | -9.3 | -15 | -16 | -15 | -3.4 | 168 | -20 | 7.3 | 6.0 | -28 | -31 | -36 | -13 | -43 | 257 | -34 | -32 | -67 | 58 | -78 | -101 | -114 | -59 | -67 | -89 | -186 | -126 | -130 | -162 | -154 | 455 | -157 | 13 | 11 | 82 | -181 | -75 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.